XENTION LTD

• France
• Healthcare
• Pharma & Biotech
• United Kingdom

XENTION LTD announced the phase 2 development of its lead atrial fibrillation programme (“AF”) is underway

CAMBRIDGE, UK, 2-9-2014 — /EuropaWire/ — XENTION LTD ("Xention"), the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating…